stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Total debt
Ascendis Pharma A/S's total debt at the end of fiscal 2025 was $986.3M, up 6.41% from $926.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $523.3M. Over the past ten years it has ranged from $41.0M (fiscal 2019) to $986.3M (fiscal 2025) — the current reading is the highest in ten years. Ascendis Pharma A/S ranks 29th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $986.3M | 6.41% |
| FY2024 | $926.9M | 57.01% |
| FY2023 | $590.4M | 10.22% |
| FY2022 | $535.6M | 350.11% |
| FY2021 | $119.0M | 6.25% |
| FY2020 | $112.0M | 173.17% |
| FY2019 | $41.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $523.3M | (50.14%) |
| Mar 2026 | $1.0B | 6.40% |
| Dec 2025 | $986.3M | 3.71% |
| Sep 2025 | $951.1M | 5.71% |
| 26 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $5.6B |
| HALO Halozyme Therapeutics, Inc. compare | $3.3B |
| BBIO BridgeBio Pharma, Inc. compare | $1.9B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| INSM Insmed, Inc. compare | $562.8M |
| ASND Ascendis Pharma A/S | $523.3M |
| BNTX BioNTech SE Sponsored ADR compare | $414.1M |
| EXEL Exelixis, Inc. compare | $191.0M |
| SMMT Summit Therapeutics PLC compare | $100.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement